O
OMEICOS Therapeutics
Prevention and treatment of cardiovascular diseases
About OMEICOS Therapeutics
OMEICOS Therapeutics is a biotechnology company focused on developing innovative therapies for cardiovascular, inflammatory, and mitochondrial diseases, which have high unmet medical needs. The company leverages its proprietary approach to target critical cell protective pathways and utilizes its industry-leading expertise in omega-3 fatty acid metabolism. OMEICOS's lead compound, OMT-28, has shown promising results and is a key part of their therapeutic pipeline. The company primarily serves the healthcare and pharmaceutical markets, aiming to provide advanced treatment options that address significant gaps in current medical therapies. OMEICOS operates on a business model that includes research and development, clinical trials, and partnerships with other biotech firms and pharmaceutical companies. Revenue is generated through licensing agreements, collaborations, and potential future sales of their therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 73.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Risk Management, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jul 2023 | $2.8M | — | Undisclosed | ↗ |
| SERIES C✓Equity / VC | Nov 2018 | $17M | $68M | Forbion Capital Partners · Vesalius Biocapital Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for OMEICOS Therapeutics is 230 monthly website visits, down 43.9% over the last three months. OMEICOS Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
OMEICOS Therapeutics in the Berlin ecosystem
The OMEICOS Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A5 investors entered at this stage
Vesalius Biocapital Partners
KfW
IBB Ventures
VC Fonds Kreativwirtschaft
Remiges Ventures
Series B and later1 investor entered at this stage
Forbion Capital Partners
Other known investors3 additional known investors
Max Delbrück Center for Molecular Medicine
Helmholtz Association - Helmholtz Gemeinschaft
German Federal Ministry of Research, Technology and Space
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OMEICOS Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OMEICOS Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











